Moreover, an engineered oncolytic adenovirus, SD55-H19, designed to overexpress H19, revealed notable antitumor activity against ICCA, underscoring its potential as a novel targeted therapeutic approach. The gene discussed is H19; the disease is infantile convulsions and choreoathetosis.